- Home
- News
- us virgislands
- injectable formulation
Injectable Formulation Articles & Analysis
13 news found
As the new academic year looms on the horizon, CD Formulation is ecstatic to announce a special Back to School Promotion 2024. ...
With a focus on sustained and controlled release formulations, as well as liquid, semi-solid, injectable, and nanoformulations, CD Formulation is at the forefront of the industry's efforts to enhance drug efficacy. ...
This innovation is particularly promising for delivering sensitive drugs that may degrade when exposed to traditional injection methods. For drugs that require a solid delivery system, CD Formulation has developed solid microneedle technology. ...
Long-Acting Controlled-Release Injection Technologies Another groundbreaking development by CD Formulation is its long-acting controlled-release injection technologies. By combining the benefits of sustained release with the ease of injection, CD Formulation has developed a solution that addresses the limitations ...
These include favoring agents, dispersion excipients, solubilizer excipients, surfactants, suspending agents, effervescents, emulsifiers, wetting agents, and preservatives. Excipients for Injections & Sterile Formulation For injections and sterile formulations, CD Formulation provides excipients that maintain ...
This formulation (Bupigel) prolonged bupivacaine release from the formulation in dissolution-like studies in vitro and analgesia in vivo in mouse, rat, and pig models. ...
ARAI is a versatile platform that can deliver up to 5 ml dose volumes, perform simultaneous injections of multiple, separately stored drug formulations, and automatically reconstitute drugs formulated in dry form. ...
” The objectives of these studies were to provide safety and immune response data for single injections of different formulations of the AV-COVID-19 SARS-CoV-2 vaccine and to also establish the feasibility of preparing personal dendritic cell vaccines at point-of-care. ...
” To date, Aktiv has met several critical milestones in the TXA autoinjector program, including development of a proprietary formulation, performing stability studies, and completing a number of promising preclinical studies. ...
Cohort 4 also included patients treated with a new “thaw-and-inject” formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. ...
OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. ...
CJ Wang, CEO, Frontier Biotechnologies said, "Today's announcement marks an important milestone in our efforts to create a long-acting injectable for treatment-experienced PLHIV (Patients Living with HIV) and critically ill, hospitalized AIDS patients who have limited choices for antiretroviral treatment. ...
This transformation is achieved by adding certain compounds that enhance the vaccines’ efficacy and the body’s tolerance when they are injected. The stability of certain compounds requires careful inertization of the formulations. Inertization consists of injecting an inert gas, most often nitrogen, into a head space in order to displace the ...